Combination therapy

18:

• A kit comprising:
• (A) a first component which comprises, as an active agent, propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically-acceptable salt thereof;
• and (B) a second component which comprises, as an active agent, an interferon.

19:

• A kit according to claim 18, for use in the treatment of a proliferative disorder.

20:

• A composition comprising:
• (A) a first component which comprises, as an active agent, propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically-acceptable salt thereof;
• and (B) a second component which comprises, as an active agent, an interferon.

21:

• A composition according to claim 20, for use in the treatment of a proliferative disorder.

22-23. (canceled)